Mammalian target of rapamycin (mTOR) antagonists Review uri icon

Overview

MeSH Major

  • Antibiotics, Antineoplastic
  • Breast Neoplasms
  • Protein Kinase Inhibitors
  • Protein Kinases
  • Sirolimus

abstract

  • Mammalian target of rapamycin (mTOR) is a serine-threonine kinase member of the cellular phosphatidylinositol 3-kinase (PI3K) pathway, which is involved in multiple biologic functions such as transcriptional and translational control. mTOR is a downstream mediator in the PI3K/Akt signaling pathway and plays a critical role in cell survival. In breast cancer this pathway can be activated by membrane receptors, including the HER (or ErbB) family of growth factor receptors, the insulin-like growth factor receptor, and the estrogen receptor. There is evidence suggesting that Akt promotes breast cancer cell survival and resistance to chemotherapy, trastuzumab, and tamoxifen. Rapamycin is a specific mTOR antagonist that targets this pathway and blocks the downstream signaling elements, resulting in cell cycle arrest in the G1 phase. Targeting the Akt/PI3K pathway with mTOR antagonists may increase the therapeutic efficacy of breast cancer therapy.

publication date

  • September 2004

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC549184

Digital Object Identifier (DOI)

  • 10.1186/bcr927

PubMed ID

  • 15318929

Additional Document Info

start page

  • 219

end page

  • 24

volume

  • 6

number

  • 5